RxDoctor Payments DataLook up a doctor →

Peter Bellafiore, MD

Neurology · Wakefield, RINPI 1881753135

Payments from drug & device makers

$273,957in general payments, 2019–2025

Across 1,419 payments — averaging $193.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$57K
  • Acadia Pharmaceuticals Inc$52K
  • Lilly USA, LLC$51K
  • Amgen$37K
  • Eisai Inc.$27K
  • Acorda Therapeutics, Inc$16K
  • plus $35K from 54 others

What the payments were for

  • Consulting fees$17,4256%
  • Speaking & faculty fees$214,71078%
  • Grants$880%
  • Travel & lodging$10,3414%
  • Food & beverage$31,17611%
  • Education$2180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)254$56,618
Acadia Pharmaceuticals Inc79$51,642
Lilly USA, LLC152$51,212
Amgen(2 entities)108$36,602
Eisai Inc.75$26,958
Acorda Therapeutics, Inc48$16,085
Teva Pharmaceuticals USA, Inc.77$7,764
Biohaven Pharmaceuticals, Inc.23$6,916
EMD Serono, Inc.58$2,775
Sunovion Pharmaceuticals Inc.50$2,762
Biohaven Pharmaceutical Holding Company Ltd.11$2,113
Novartis77$1,123
Lundbeck LLC15$898
UCB, Inc.26$793
Amneal Pharmaceuticals LLC51$739
Biogen28$730
Neurocrine Biosciences, Inc.24$706
Sanofi17$670
Neurelis, Inc.9$556
Pfizer33$474
SK Life Science, Inc.16$424
Kyowa Kirin, Inc.9$424
Johnson & Johnson9$370
Mallinckrodt Enterprises LLC5$309
Jazz Pharmaceuticals Inc.6$301
Otsuka America Pharmaceutical, Inc.11$291
Bristol Myers Squibb11$272
E.r. Squibb & Sons, L.L.C.5$261
Catalyst Pharmaceuticals, Inc.5$229
Avanir Pharmaceuticals, Inc.13$210
Medtronic(2 entities)3$210
MDD US Operations, LLC8$199
CSL Behring4$175
GE HealthCare10$172
Banner Life Sciences, LLC4$172
Arbor Pharmaceuticals, Inc.10$159
Adamas Pharmaceuticals, Inc.8$158
Impel Pharmaceuticals Inc.4$153
Livanova USA, Inc.1$150
Supernus Pharmaceuticals, Inc.5$131
Upsher-smith Laboratories LLC8$126
Sumitomo Pharma America, Inc.7$114
Boston Scientific1$84
Axsome Therapeutics, Inc.3$74
Avion Pharmaceuticals4$69
Almatica Pharma LLC3$55
Assertio Therapeutics, Inc.3$52
Merz Pharmaceuticals, LLC2$48
Azurity Pharmaceuticals, Inc.3$48
Harmony Biosciences LLC3$44
TG Therapeutics, Inc.2$39
Mallinckrodt Hospital Products Inc.1$34
Sanofi-aventis U.S. LLC2$32
Alnylam Pharmaceuticals Inc.2$31
AstraZeneca2$30
Promius Pharma LLC2$28
Otsuka Pharmaceutical Development & Commercialization, Inc.1$25
Insightec,inc1$20
Vanda Pharmaceuticals Inc.1$19
Portola Pharmaceuticals, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$273,957 in reported general payments places this provider in the 95th percentile of 86 neurology providers in Rhode Island.

See all neurology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$92,832
Medicare patients
311
Services billed
4,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate63$349,190
UbrelvyUbrogepant132$187,245
Nurtec OdtRimegepant Sulfate76$143,230
Emgality PenGalcanezumab-Gnlm135$96,267
BotoxOnabotulinumtoxina70$91,418
QuliptaAtogepant30$43,722
FycompaPerampanel27$38,965
RytaryCarbidopa/Levodopa27$29,998
NuedextaDextromethorphan Hbr/Quinidine16$26,474
GlatopaGlatiramer Acetate17$25,217
Glatiramer Acetate13$18,122
Aimovig AutoinjectorErenumab-Aooe20$18,004
Emgality SyringeGalcanezumab-Gnlm23$15,525
Lacosamide75$14,471
Rasagiline Mesylate43$12,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$51,642$349,19063 claims
AbbVieUbrelvy, Botox, Qulipta$56,618$322,385232 claims
PfizerNurtec Odt$474$143,23076 claims
Eisai Inc.Fycompa$26,958$38,96527 claims
Amneal Pharmaceuticals LLCRytary$739$29,99827 claims
Avanir Pharmaceuticals, Inc.Nuedexta$210$26,47416 claims
Arbor Pharmaceuticals, Inc.Horizant$159$6,94513 claims
Upsher-smith Laboratories LLCTopiramate$126$2,878181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 86 neurology providers in Rhode Island.

Other neurology in Wakefield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →